# Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure

Study · id `cardio:ct-nct03445949` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03445949](<https://clinicaltrials.gov/study/NCT03445949>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03445949

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT03445949. Randomized; no masking; primary purpose treatment. Start 2018-01-23 (actual); primary completion 2025-06-23 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT03445949, source copy `cardio:ctgov-nct03445949-2023-07-11`, retrieved 2026-10-26)
- Started: 2018-01-23 (actual) (ClinicalTrials.gov record NCT03445949, source copy `cardio:ctgov-nct03445949-2023-07-11`, retrieved 2026-10-26)
- Primary completion: 2025-06-23 (anticipated) (ClinicalTrials.gov record NCT03445949, source copy `cardio:ctgov-nct03445949-2023-07-11`, retrieved 2026-10-26)
- Completion: 2027-06-23 (anticipated) (ClinicalTrials.gov record NCT03445949, source copy `cardio:ctgov-nct03445949-2023-07-11`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT03445949, source copy `cardio:ctgov-nct03445949-2023-07-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03445949-2023-07-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure
- Acronym: SAFE-LAAC
- Condition: Atrial Fibrillation
- Intervention (Drug): short postimplantation dual antiplatelet therapy
- Intervention (Drug): extended postimplantation dual antiplatelet therapy
- Intervention (Drug): long-term treatment with a single antiplatelet agent
- Intervention (Drug): 6 months treatment with a single antiplatelet agent
- Lead sponsor: National Institute of Cardiology, Warsaw, Poland
- Lead sponsor class: OTHER
- Collaborator: Medical Research Agency, Poland
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: National Institute of Cardiology, Warsaw, Poland (`cardio:org-national-institute-of-cardiology-warsaw-poland`)
- Registry lists this organization as a collaborator: Medical Research Agency, Poland (`cardio:org-medical-research-agency-poland`)

## Provenance

Content hash: 6261fa35dc7b02bfa59557182fd42191d615fc6dd743bf4a83d53cceff4f0a92
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
